187 results about "Sarcosine" patented technology

The invention discloses an oral care desensitization paste and a preparation method thereof, and mainly relates to the technical field of dental medicines. The oral care desensitization cream is prepared from the following components: bioactive glass, strontium chloride, sodium chloride, silicon dioxide, sodium carboxymethyl cellulose, polyethylene glycol 400, a xanthan gum solution, sodium lauryl sulfate, sodium lauroyl sarcosinate, titanium dioxide, beta-glucan, saccharin sodium salt, sorbitol, methylparaben, propyl hydroxybenzoate, edible essence and water. Compared with the prior art, the oral care desensitization paste disclosed by the invention can be used for sealing dentinal tubules and treating hemodia; the traditional Chinese medicine composition can also be used for treating plaque gingivitis, relieving and reducing gingival bleeding and inhibiting and reducing dental plaque; and meanwhile, the condition of mistakenly swallowing and eating in the using process is reduced.

The invention relates to the technical field of metal working fluids, in particular to a degradable environment-friendly vegetable oil-based semi-synthetic cutting fluid and a preparation method thereof. The cutting fluid comprises 20-30 parts of vegetable lubricating oil, 10-20 parts of an alkali storage agent, 2-5 parts of a corrosion inhibitor, 3-5 parts of a coupling agent, 5-8 parts of a surfactant and 6-11 parts of a composite anti-rust agent, the composite anti-rust agent comprises an anti-rust agent A and an anti-rust agent B, the anti-rust agent A comprises N-[3-(dimethylamino) propyl]-N, N-dimethylformamide, and the anti-rust agent B comprises N-[3-(dimethylamino) propyl]-N, N-dimethylformamide. The antirust agent A comprises at least one of N, N ', N'-trimethyl-1, 3-propanediamine, benzotriazole, sebacic acid and 2, 4, 6-tri (aminocaproic acid)-1, 3, 5-triazine, and the antirust agent B comprises at least one of an imidazoline compound and fatty acid sarcosine ester. The cutting fluid provided by the invention has excellent corrosion resistance, rust resistance, defoaming property, biodegradability and storage stability, and has a good application prospect.

The invention discloses a diagnosis model for hepatocellular carcinoma microvascular invasion and a construction method and application thereof, and belongs to the technical field of medical examination. Metabolite in the blood of a hepatocellular carcinoma patient is taken as a cut-in, preoperative clinical tumor indexes are combined, it is found that PIVKA-II, GGT, L-Serine, Sarcosine and tumor sizes have important significance on formation of hepatocellular carcinoma MVI, a diagnosis model based on multiple omics and multiple dimensions is established based on the diagnosis indexes, the diagnosis model is used for diagnosis of the preoperative MVI of the hepatocellular carcinoma patient, and the diagnosis model is used for diagnosis of the preoperative MVI of the hepatocellular carcinoma patient. The defects of existing diagnosis means in the aspect of preoperative diagnosis are overcome, and a more timely and accurate basis is provided for clinical decision making.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The invention discloses a PSA electrotinning insoluble anode system and a production method of an electrotinning plate, and relates to the technical field of electrotinning. The PSA tin electroplating insoluble anode system comprises an electroplating additive which is composed of benzotriazole, N-oleoyl sarcosine, S-carboxyethyl thiosuccinic acid and sodium citrate. The problems of serious black ash and poor coating performance of an electroplated tin plate product are solved, the tin plating stability of a plating solution in an electroplating bath is improved, the black ash on the surface of the electroplated tin plate product can be effectively reduced, the requirements of low black ash and high adhesive force on the surface of an electroplated tin plate of a PSA (Pressure Swing Adsorption) electroplated tin insoluble anode system are met, and the service life of the electroplated tin plate is prolonged. The electroplated tin plate produced through the PSA electroplated tin insoluble anode system is bright and clean in plating layer surface, and after the tin layer surface with the thickness of 8.4 g / m < 2 > and below is wiped through test paper, the reduction percentage of the test paper whiteness caused by black ash is smaller than or equal to 10%.

The invention provides a reagent and a method for enhancing the tolerance of a PCR (Polymerase Chain Reaction) inhibitor and application. The reagent comprises arginine and sodium lauroyl sarcosinate, the method comprises the step of adding arginine and sodium lauroyl sarcosinate into a reagent for PCR (Polymerase Chain Reaction) amplification. The reagent disclosed by the invention has relatively strong tolerance to interference of inhibitors such as non-target nucleic acid and the like. The method is simple to operate, low in cost and high in nucleic acid detection sensitivity. The reagent and the method have good application prospects in detection of nucleic acid extracted from samples such as whole blood, urine, sputum and the like.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The present invention is in the field of cosmetics and in particular relates to combinations of one or more alkylamidothiazoles and one or more sarcosine alkyl esters and cosmetic formulations containing such combinations. It has been found that the sarcosine alkyl esters significantly increase the solubility of alkylamidothiazoles in cosmetic formulations.

The invention provides a construction method and application of a mouse gastric cancer spontaneous tumor model, and the construction method comprises the following steps: reducing or inhibiting the expression quantity of a TP53 gene and / or the activity of a P53 protein in a mouse body, and then giving a drug to the mouse for chemical induction to obtain the mouse gastric cancer spontaneous tumor model. Wherein the drug contains sodium nitrite and ethyl sarcosinate, and / or the drug contains an N-nitroso compound. According to the construction method of the mouse gastric cancer spontaneous tumor model, the construction of the C57 mouse gastric cancer spontaneous tumor model by using the NESS is proposed for the first time, and the tumor formation rate can reach 75% or above; the tumor formation period is short and is about 3-4 months, and the construction cost is low.

The invention provides a metabonomics-based preeclampsia risk assessment prediction model construction method, a prediction model, application of metabolites, a metabolite detection kit, a prediction product, a prediction system and related application thereof. Specifically, clinical indexes and metabolite data of a pregnant woman serve as input, whether the pregnant woman suffers from preeclampsia or not serves as output, model construction is conducted through a machine learning method, and a preeclampsia risk assessment and prediction model is obtained. The metabolite is selected from at least one of 4-hydroxyphenyllactic acid, homovanillic acid, ornithine, sarcosine, adenosine monophosphate and 3-methylbutyryl carnitine. According to the invention, not only are six metabolite markers strongly associated with preeclampsia found, but also effective prediction of early preeclampsia and late preeclampsia is realized by establishing a prediction model, and the method has extremely high clinical value.

The invention relates to the technical field of face cleansing gels, in particular to a hexagonal liquid crystal face cleansing gel and a preparation method thereof.The hexagonal liquid crystal face cleansing gel at least comprises, by mass, a phase A: 20-26% of sodium lauroyl sarcosinate and 0-1.5% of an auxiliary surfactant; a phase B: 3-8% of propylene glycol laurate; a phase C: 0.01%-4.5% of glycerol laurate; phase D: 1 to 5 percent of polyglycerol-2 laurate; 0-2% of an auxiliary agent; and deionized water: complementing the balance. By optimizing a product formula system, an amino acid cleansing product which has a transparent appearance similar to that of micelle type amino acid cleansing cream, can not depend on addition of a large number of polymers to assist thickening and shows a non-flowing appearance texture is prepared, and the amino acid cleansing product has extremely high market application and popularization value.

The invention belongs to the technical field of sarcosine detection, and relates to an integrated sarcosine detection device as well as a preparation method, a detection method and application thereof. The device consists of a sample bottle and a double-layer paper chip, wherein the double-layer paper chip is fixed in a bottle cap of the sample bottle; the double-layer paper chip comprises a target recognition layer and a detection layer, the target recognition layer is Whatman 1 # filter paper loaded with SOx / HRP-coated MAF-7 biological composite materials, the detection layer is Whatman 1 # filter paper loaded with TMB color developing agents, and the layers are bonded through water-soluble double-faced adhesive tapes. After a sample is added into the sample bottle, the bottle is turned over, SOx can recognize and oxidize sarcosine to obtain H2O2, after the double-sided adhesive tape is fully reacted and dissolved, HRP oxidizes a substrate TMB in the presence of H2O2 to generate a bright blue product oxTMB, and RGB signals are recorded through a handheld colorimeter. The detection device can be used for quantitatively detecting the sarcosine content of the prostatic cancer marker.

The invention relates to the technical field of sodium sarcosine, in particular to slow-release sodium sarcosine and a preparation method thereof. The slow-release sodium sarcosine is prepared from the following raw materials in parts by weight: 70 to 80 parts of sodium sarcosine aqueous solution, 5 to 10 parts of acrylic acid, 5 to 10 parts of acrylamide, 3 to 5 parts of hydrotropy monomer A, 0.5 to 1 part of hydrotropy monomer B, 0.05 to 0.15 part of cross-linking agent and 0.05 to 0.15 part of initiator, and the hydrotropy monomer B is a mixture of diallyl dimethyl ammonium chloride and methacryloyloxyethyl trimethyl ammonium chloride. The sustained-release sodium sarcosinate disclosed by the invention has relatively high drug loading capacity and encapsulation efficiency, does not generate a burst release phenomenon, and can act for a relatively long time in vivo, so that the benefits of the sustained-release sodium sarcosinate are better exerted, the intake frequency is reduced, and the sustained-release sodium sarcosinate has a wide application prospect.

This invention provides a continuous method for preparing high-purity creatine monohydrate, comprising the following steps: a) adding chloroacetic acid aqueous solution dropwise to an aqueous methylamine solution, stirring at room temperature for 2 hours after the addition is complete; b) heating to 50-60°C and holding for 1 hour to remove most of the methylamine, then heating to 95°C to evaporate the methylamine aqueous solution for 1 hour; c) adding sodium hydroxide solution dropwise to the solution from step b) at 95°C, then heating to 105°C and concentrating under reduced pressure for 1.5 hours to approximately half the original volume, obtaining a creatine solution with a concentration of 30%-40%; d) cooling the solution from step c) to 40-60°C and adding a catalyst; e) drying to obtain pure creatine monohydrate. This invention reduces the methylamine equivalent, saving costs, and eliminates the need for purifying creatine for direct use in the next reaction; it can simultaneously lower the system reaction temperature and pH value to inhibit the formation of byproducts dicyandiamide and creatinine, and eliminates the need for debittering agents for purification and debittering, thus saving production costs.

The invention belongs to the technical field of biosensors, and provides molecularly imprinted hydrogel for sarcosine detection, a micro-strain conduction sensor and a preparation method of the micro-strain conduction sensor. The hydrogel is prepared by the following steps: carrying out photo-initiation polymerization on a gel pre-polymerization solution containing a 4-vinylpyridine monomer, a 2-acrylamide-2-methylpropanesulfonic acid monomer, an acrylamide monomer, sarcosine template molecules, a cross-linking agent and a photoinitiator, and washing to remove the sarcosine template molecules. The micro strain conduction sensor is composed of a hydrogel layer and a resistance strain gauge, and the hydrogel layer is chemically bonded to one side of the resistance strain gauge and completely covers sensitive grid wires of the resistance strain gauge. The hydrogel disclosed by the invention has excellent specific recognition capability on sarcosine, and high-sensitivity and high-selectivity detection of sarcosine in a complex matrix sample can be realized through the micro strain conduction sensor disclosed by the invention.

The invention relates to a creatine monohydrate preparation method, which comprises: S1, carrying out a first reaction on a methylaminoacetonitrile aqueous solution and a first sodium hydroxide aqueous solution to obtain a sodium sarcosinate-containing aqueous solution; s2, carrying out separation treatment on the aqueous solution containing sodium sarcosine in the step S1 by adopting a bipolar membrane electrodialysis device to obtain an aqueous solution containing sarcosine and a second sodium hydroxide solution; and S3, carrying out a second reaction on the aqueous solution containing sarcosine in the step S2 and cyanamide to obtain a crude product containing sarcosine monohydrate. The creatine monohydrate prepared by the preparation method provided by the invention is high in purity and does not contain dicyandiamide and creatinine impurities, and the total yield of the creatine monohydrate is 90% or above.

This invention relates to the field of hair care products technology, specifically disclosing a plant-based compound fermented oil-controlling and volumizing shampoo and its preparation process. The raw materials, by weight, include: 15-25 parts sodium lauroyl sarcosinate, 8-15 parts potassium cocoyl glycinate, 10-18 parts soapberry fruit fermentation liquid, 6-12 parts arborvitae leaf fermentation extract, 5-10 parts rosemary leaf fermentation liquid, 3-6 parts hydrolyzed oat protein, 2-5 parts panthenol, 0.1-0.5 parts piroctone olamine, 0.2-0.6 parts xanthan gum, 0.4-0.8 parts phenoxyethanol, and 40-60 parts deionized water. This invention utilizes a triple plant-based low-temperature anaerobic fermentation process, combined with a mild amino acid surfactant system, to provide multiple benefits including gentle cleansing, long-lasting oil control, hair root lifting, and scalp care. It is suitable for oily scalps and fine, limp hair.

The utility model relates to the field of crystallization kettles, in particular to a sarcosine crystallization kettle. Comprising an adjusting device, the adjusting device comprises a fixing rod, the fixing rod is fixedly connected with a crystallization kettle body, the end, away from the crystallization kettle body, of the fixing rod is fixedly connected with a connecting frame, the inner wall of the connecting frame is fixedly connected with a supporting plate, and the side, away from a discharging port, of the supporting plate is fixedly connected with a motor; the output end of the motor is fixedly connected with a rotating rod, the arc surface of the rotating rod is in threaded connection with a fixing ring, and one end of the arc surface of the fixing ring is fixedly connected with an adjusting plate. The sarcosine crystallization kettle provided by the utility model has the advantages that when the crystallization kettle is used for crystallizing amino acid, stirring can be carried out on the discharge hole of the crystallization kettle through the adjusting device, and good flowability of materials can be kept and the particle discharge speed can be accelerated through stirring, so that the discharge time can be shortened, and the overall production efficiency can be improved.

Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

The present invention provides synthetic peptides, compositions containing synthetic peptides, and methods for modifying the complement system. [Solution] The present invention relates to the modification of a 15-amino acid synthetic peptide from polar assortant (PA) peptides, which are scrambled peptides derived from human astrovirus protein. In some embodiments, the present invention relates to peptides that are modified PAs, which are stapled and / or have D-enantiomer substitutions of certain amino acids, and which include sarcosine substitutions at certain amino acid positions. The present invention further provides a method for selecting at least one synthetic peptide to treat various conditions.

This invention provides a composition for balancing skin sebum secretion, its preparation method, and its application. The composition comprises the following components: Lactobacillus fermentation lysate, yeast / zinc fermentation product, niacinamide, zinc PCA, medicinal spore extract, *Salix friesiensis* extract, capryloyl glycine, Ceylon cinnamon bark extract, and sarcosine. The composition for balancing skin sebum secretion provided by this invention utilizes multiple oil-controlling ingredients to inhibit sebum secretion through multiple pathways, while also possessing certain moisturizing and soothing effects.

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

The invention discloses a universal sample type nucleic acid releasing agent and application thereof. The nucleic acid releasing agent is prepared from the following components in molar concentration: 20 to 100 mM of Tris-HCl, 30 to 500 mM of sodium chloride, 30 to 200 mM of ammonium sulfate, 1 to 6 mM of EDTA (Ethylene Diamine Tetraacetic Acid), 1 to 8 mM of a reducing agent, 0.1 to 0.2 percent of sodium dodecyl sarcosinate, 0.1 to 3 mM of Surfactin, 5 to 30 percent of Chelex-100 and 5 to 15 percent of trehalose. According to the method, various samples can be mildly split, impurities such as impure proteins and lipids can be effectively removed, the complexity of nucleic acid samples is reduced, and the method is seamlessly jointed with subsequent PCR (Polymerase Chain Reaction); the kit has double effects of sample preservation and splitting decomposition, can strongly inhibit various nuclease, and can ensure the long-term storage stability of samples.

Provided is a cyclic peptide, which has a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysine; and X6 is selected from a group consisting of tyrosine, valine, and glutamic acid. Provided is a preparation method for the cyclic peptide. Provided is a complex, comprising the cyclic peptide, a linker, and a chelating agent. Provided is a use of the complex as a radionuclide-labeled targeting molecule. Provided is a radionuclide labeling method, comprising bringing a complex that chelates a radionuclide into contact with an object to be labeled by the radionuclide.

The invention provides a whitening composition as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. According to the whitening composition provided by the invention, the isopropyl lauroyl sarcosinate, the diisopropyl sebacate, the PPG-14 polyglycerol-2 ether, the bis-diethoxy diglycol cyclohexane 1, 4-dicarboxylate and the poly C10-30 alkanol acrylate are used as oil phases to wrap the whitening components (magnolol, pterostilbene, ferulic acid and dimethyl methoxy benzodihydropyranol) so as to form oil sacs, so that the whitening composition can be used for whitening the skin; and then dispersing in a polyhydric alcohol and carbomer matrix to control the composition of the oil phase and the whitening component, so that the whitening effect and the transdermal absorption effect of the whitening composition are improved.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The invention relates to the technical field of nucleic acid detection, in particular to a lysis buffer solution, a kit and an extraction method for extracting free DNA of peripheral blood. The lysis buffer solution for extracting the free DNA of the peripheral blood comprises a first lysis solution and a second lysis solution, the first lysis solution takes guanidine hydrochloride as a main chaotropic agent and at least one of ammonium thiocyanate and guanidine isothiocyanate as an auxiliary chaotropic agent, and is compounded with a metal ion chelating agent, trehalose, dithiothreitol, digestive enzyme, sodium dodecyl sarcosinate, borate and ascorbic acid; the second lysis solution takes guanidine hydrochloride as a main chaotropic agent and urea as an auxiliary chaotropic agent, and is compounded with a metal ion chelating agent, trehalose, dithiothreitol, digestive enzyme, sodium dodecyl sarcosinate, borate, ascorbic acid and polyethylene glycol. The buffer solution of the lysate does not contain SDS (sodium dodecyl sulfate), so that the residue of SDS in an extracted product can be avoided, and the amount of extracted free DNA (deoxyribonucleic acid) is more.

To provide a novel skin cleansing agent, particularly one that leaves the skin feeling smooth after washing. [Solution] (A) Oleoyl sarcosine or its salt (B) Polyglycerol fatty acid esters in which two or more fatty acids are bonded together. A skin cleansing agent containing at least [a certain ingredient].

The present invention relates to a novel liposome composition and its application in cosmetics, and the liposome composition comprises an active ingredient, sodium stearoyl glutamate and isopropyl lauroyl sarcosinate.

The present invention aims to provide a liquid oral composition that can suppress the reduction in flavor expression caused by glycyrrhizic acid or its salts by incorporating acyl amino acids or their salts. [Solution] A liquid oral composition comprising: (A) component: at least one selected from the group consisting of glycyrrhizic acid and its salts; (B) component: at least one selected from the group consisting of acyl amino acids and their salts; and (C) component: a fragrance, wherein the ratio of the content of component (A) to the content of component (B) is 0.625 to less than 2.2 when component (B) contains acyl sarcosine and its salts, and 0.03 to less than 5 when component (B) does not contain acyl sarcosine and its salts, and substantially free of ethyl alcohol.